Bad Saarow

• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N … Ended recruitment
  2024-510947-71-00 5 2022-11-21 Chronic Myeloid Leukemia
• Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended recruitment
  2024-512704-20-00 4 2020-06-22 Unresectable and/or metastatic soft-tissue sarcoma after failure of at
• Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined … Ended recruitment
  2024-511577-29-01 5 2020-03-13 intermediate and high-risk rectal cancer
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno … Ended recruitment
  2023-503670-21-00 5 2019-08-28 Patients with newly diagnosed AML and intermediate- or adverse-risk ge
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma
• DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended recruitment
  2024-514945-12-00 10 2018-09-03 locally advanced resectable adenocarcinoma of the oesophagogastric jun
• L19TNF plus doxorubicin in patients with STS Ended recruitment
  2024-512789-32-00 5 2017-10-09 Unresectable or metastatic soft tissue sarcoma
• „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion prot … Ended recruitment
  2024-516026-56-00 3 2017-08-17 Histologically confirmed locally advanced or metastatic solid tumor (S
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJ … Ended
  2024-511847-24-00 4 2022-05-23 Biliary tract cancer
• RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended
  2023-505441-69-00 5 2022-05-17 refractory, advanced gastro-oesophageal cancer
• Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom … Ended
  2024-511361-11-00 10 2022-03-25 Advanced dedifferentiated liposarcoma
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of … Ended
  2024-512934-14-00 5 2016-11-07 advanced or metastatic adenocarcinoma of the stomach or gastroesophage
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma

Showing 25–42 of 42 trials